New combo therapy targets Hard-to-Treat prostate cancer

NCT ID NCT05613894

Recruiting now Disease control Sponsor: University of Utah Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 23, 2026 · Updated 22 times

Summary

This study is for men with a type of advanced prostate cancer that has spread and is no longer controlled by hormone therapy. The researchers are testing a combination of two drugs: cabozantinib (a pill that blocks cancer growth) and a radioactive drug called 177Lu-PSMA-617 (which targets and kills cancer cells). The goal is to find the safest dose and see if the combination can help stop the cancer from growing. About 33 men will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Huntsman Cancer Institute at University of Utah
RECRUITING

Salt Lake City, Utah, 84112, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION RESISTANT PROSTATE CANCER